Summit Therapeutics Inc. (SMMT) Bundle
A Brief History of Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT), a biopharmaceutical company, focuses on developing innovative therapies for serious diseases. As of 2024, the company has a significant history marked by strategic partnerships, research advancements, and fluctuating financial performance.
Company Formation and Early Developments
Founded in 2003, Summit Therapeutics initially concentrated on antibiotics. Over the years, it shifted its focus towards developing treatments for Duchenne muscular dystrophy (DMD) and other diseases. A pivotal moment in the company’s history was the acquisition of the rights to the drug candidate, ivonescimab, in January 2023, which marked a strategic pivot to oncology.
Financial Performance Overview
As of September 30, 2024, Summit reported a net loss of $160.1 million for the nine months ended, compared to a net loss of $578.4 million in the same period of 2023. The reduction in losses indicates a focus on cost management and operational efficiency.
| Financial Metric | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| Net Loss | $160.1 million | $578.4 million |
| Research and Development Expenses | $99.4 million | $34.7 million |
| General and Administrative Expenses | $46.1 million | $18.7 million |
Capital Structure and Stock Performance
As of September 30, 2024, Summit Therapeutics had 737,094,965 shares outstanding, reflecting an increase from 701,660,053 shares at the end of 2023. The company's total stockholders' equity amounted to $437.9 million, significantly up from $77.7 million at the end of the previous year.
Research and Development Focus
Summit's primary research and development expenses for the nine months ended September 30, 2024, amounted to $99.4 million. This figure includes substantial investments in ivonescimab, which is under development for various cancer indications.
| Research and Development Expense Breakdown | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| Oncology | $64.8 million | $19.3 million |
| Compensation Related Costs | $22.6 million | $14.7 million |
| Stock-Based Compensation | $11.8 million | $2.0 million |
Liquidity and Capital Resources
As of September 30, 2024, Summit Therapeutics reported cash and cash equivalents of $93.8 million and short-term investments in U.S. Treasury securities totaling $393.1 million. The company generated $404.8 million in net cash from financing activities during the nine months ended September 30, 2024, largely due to private placements.
Future Outlook
Summit Therapeutics is positioned to continue its focus on oncology and other therapeutic areas. The company plans to utilize its available liquidity to support ongoing research and development efforts and potentially expand its product pipeline.
A Who Owns Summit Therapeutics Inc. (SMMT)
Major Shareholders
As of September 30, 2024, the ownership structure of Summit Therapeutics Inc. (SMMT) reflects significant involvement from key executives and institutional investors. Below is a detailed breakdown of the major shareholders:
| Shareholder | Shares Owned | Percentage Ownership |
|---|---|---|
| Robert W. Duggan (CEO, Executive Chairman) | 3,325,991 | 0.45% |
| Dr. Mahkam Zanganeh (CEO, President) | 44,052 | 0.006% |
| Manmeet Soni (COO, CFO) | 44,052 | 0.006% |
| Jeff Huber (Board Member) | 44,052 | 0.006% |
| Caspian Capital LLC (controlled by Jeff Huber) | 44,052 | 0.006% |
| Institutional Investors | Approximately 45% (various institutions) | 45% |
| Other Shareholders | Approximately 54.5% | 54.5% |
Recent Stock Offerings
On September 11, 2024, Summit Therapeutics completed a private placement, issuing 10,352,418 shares at a purchase price of $22.70 per share, resulting in gross proceeds of approximately $235 million.
Stock Performance
The stock performance of SMMT as of September 30, 2024, indicates a market capitalization of approximately $1.66 billion based on the share price at that time.
Financial Overview
As of September 30, 2024, Summit Therapeutics reported:
- Cash and cash equivalents: $93.8 million
- Short-term investments: $393.1 million
- Accumulated deficit: $(1,153.4) million
- Total stockholders' equity: $437.9 million
Summit reported a net loss of $56.3 million for the three months ended September 30, 2024.
Future Financing Plans
The company has filed a shelf registration statement that allows for the sale of up to $450 million in various securities, which may include common stock and debt securities.
Warrants and Options
As of September 30, 2024, Summit Therapeutics had outstanding warrants totaling 4,945,669 shares, with a weighted average exercise price of $1.58.
Summit Therapeutics Inc. (SMMT) Mission Statement
Summit Therapeutics Inc. is dedicated to the discovery, development, and commercialization of patient-centric therapeutics aimed at addressing serious unmet medical needs. The company strives to improve the quality of life and extend the duration of life for patients through innovative medicinal therapies.
Company Overview
As of September 30, 2024, Summit Therapeutics had a total of 737,094,965 shares issued and outstanding, with a market capitalization reflective of its ongoing financial activities and strategic focus on clinical trials and product development.
Financial Performance
For the three months ended September 30, 2024, Summit reported a net loss of $56.3 million, compared to a net loss of $21.2 million for the same period in 2023. For the nine months ended September 30, 2024, the net loss was $160.1 million, down from $578.4 million in 2023. This reflects significant operational expenses primarily driven by research and development activities.
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2024, were $37.7 million, significantly higher than $15.3 million in the same period of 2023. For the nine months ended September 30, 2024, these expenses totaled $99.4 million compared to $34.7 million in 2023.
| Period | Research and Development Expenses (in millions) | General and Administrative Expenses (in millions) | Total Operating Expenses (in millions) |
|---|---|---|---|
| Three Months Ended September 30, 2024 | $37.7 | $20.4 | $58.1 |
| Three Months Ended September 30, 2023 | $15.3 | $5.4 | $20.7 |
| Nine Months Ended September 30, 2024 | $99.4 | $46.1 | $160.5 |
| Nine Months Ended September 30, 2023 | $34.7 | $18.7 | $574.3 |
Cash Position and Financing Activities
As of September 30, 2024, Summit Therapeutics held cash and cash equivalents of $93.8 million and short-term investments totaling $393.1 million. The company raised $235 million in a private placement in September 2024, along with $44.2 million from its at-the-market offering activities.
Accumulated Deficit
Summit reported an accumulated deficit of $1,153.4 million as of September 30, 2024. This figure has increased from $993.3 million at the end of 2023, reflecting ongoing investment in R&D and operational expenses.
Clinical Development Focus
The company's strategic focus includes the development of ivonescimab, with plans to initiate a Phase III clinical study in early 2025. The anticipated sample size for this study is 780 patients, targeting first-line metastatic NSCLC patients with high PD-L1 expression.
Stockholder Equity
As of September 30, 2024, the total stockholders' equity for Summit was $437.9 million, showing a notable increase from $77.7 million at the end of 2023. This increase was driven by recent capital raises and stock sales.
| Item | Amount (in thousands) |
|---|---|
| Common Stock | $7,371 |
| Additional Paid-In Capital | $1,586,227 |
| Accumulated Other Comprehensive Loss | $(2,308) |
| Accumulated Deficit | $(1,153,370) |
| Total Stockholders' Equity | $437,920 |
How Summit Therapeutics Inc. (SMMT) Works
Company Overview
Summit Therapeutics Inc. (SMMT) operates primarily in the biopharmaceutical sector, focusing on developing novel therapeutics for diseases with significant unmet medical needs. The company emphasizes its proprietary drug candidates and collaborations to enhance its research and development pipeline.
Financial Performance
As of September 30, 2024, Summit reported a net loss of $56.3 million for the third quarter and a total net loss of $160.1 million for the nine months ended September 30, 2024. The company has an accumulated deficit of $1.15 billion and total stockholders' equity of $437.9 million.
| Financial Metric | Q3 2024 (in millions) | Q3 2023 (in millions) | 9M 2024 (in millions) | 9M 2023 (in millions) |
|---|---|---|---|---|
| Net Loss | (56.3) | (21.2) | (160.1) | (578.4) |
| Operating Expenses | 58.1 | 20.7 | 160.5 | 574.3 |
| Research and Development Expenses | 37.7 | 15.3 | 99.4 | 34.7 |
| General and Administrative Expenses | 20.4 | 5.4 | 46.1 | 18.7 |
| Cash and Cash Equivalents | 93.8 | N/A | 93.8 | N/A |
| Short-term Investments | 393.1 | N/A | 393.1 | N/A |
Research and Development Activities
Summit Therapeutics is heavily invested in the development of ivonescimab (SMT112), an oncology drug candidate. The research and development expenses for this candidate increased significantly, with a total investment of $520.9 million reported for the nine months ending September 30, 2023. The company anticipates ongoing increases in R&D costs associated with this program.
| Research and Development Expenses (in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Oncology | 23.0 | 10.5 | 64.8 | 19.3 |
| Acquired In-Process R&D | — | — | 15.0 | 520.9 |
| Anti-infectives | 0.2 | (0.1) | 0.2 | (1.3) |
| Total R&D Expenses | 37.7 | 15.3 | 114.4 | 555.6 |
Capital Structure and Financing
As of September 30, 2024, Summit Therapeutics had a total of 737,094,965 shares outstanding, with an additional paid-in capital of $1.59 billion. The company has engaged in various financing activities, including a recent private placement that raised gross proceeds of $235 million and an at-the-market offering that generated $44.2 million.
Stock Options and Warrants
As of September 30, 2024, the company had 48,390,220 outstanding stock options with a weighted average exercise price of $1.77. The total intrinsic value of these options was reported at $973,991.
| Stock Options Activity | Outstanding Options | Weighted Average Exercise Price |
|---|---|---|
| Outstanding at December 31, 2023 | 46,654,220 | $1.62 |
| Granted | 2,825,000 | $4.14 |
| Forfeited | (1,089,000) | $1.34 |
| Outstanding at September 30, 2024 | 48,390,220 | $1.77 |
Liquidity and Future Outlook
Summit Therapeutics has cash and cash equivalents of $93.8 million as of the end of Q3 2024, along with short-term investments totaling $393.1 million. The company expects to continue incurring operating losses and will need to raise additional capital to support ongoing operations and product development.
How Summit Therapeutics Inc. (SMMT) Makes Money
Revenue Streams
As of 2024, Summit Therapeutics Inc. (SMMT) does not have any reported revenue from product sales. The company is primarily focused on research and development (R&D) in the pharmaceutical sector, particularly in oncology and anti-infectives.
Research and Development Expenses
Summit Therapeutics has incurred significant R&D expenses, which are essential to its business model. For the three months ended September 30, 2024, R&D expenses totaled $37.7 million, up from $15.3 million in the same period in 2023. For the nine months ended September 30, 2024, R&D expenses reached $99.4 million, compared to $34.7 million in 2023.
| Period | R&D Expenses (in millions) |
|---|---|
| Q3 2024 | $37.7 |
| Q3 2023 | $15.3 |
| 9M 2024 | $99.4 |
| 9M 2023 | $34.7 |
Acquired In-Process Research and Development
Summit Therapeutics has also made significant investments in acquired in-process research and development. For the nine months ended September 30, 2024, the company recorded an expense of $15.0 million related to this category, a substantial decrease from $520.9 million in the same period in 2023. This decrease is largely attributed to the upfront payments made for licensing agreements in the previous year.
General and Administrative Expenses
General and administrative expenses for Summit Therapeutics have increased significantly. For the three months ended September 30, 2024, these expenses were $20.4 million, up from $5.4 million in Q3 2023. For the nine months ended September 30, 2024, general and administrative expenses totaled $46.1 million, compared to $18.7 million in 2023.
| Period | G&A Expenses (in millions) |
|---|---|
| Q3 2024 | $20.4 |
| Q3 2023 | $5.4 |
| 9M 2024 | $46.1 |
| 9M 2023 | $18.7 |
Net Loss
Summit Therapeutics reported a net loss of $56.3 million for the three months ended September 30, 2024, compared to a loss of $21.2 million in the same period in 2023. The nine-month net loss for 2024 was $160.1 million, compared to $578.4 million in 2023.
| Period | Net Loss (in millions) |
|---|---|
| Q3 2024 | $56.3 |
| Q3 2023 | $21.2 |
| 9M 2024 | $160.1 |
| 9M 2023 | $578.4 |
Funding Sources
Summit Therapeutics has financed its operations through various methods, including private placements and at-the-market offerings. In September 2024, the company raised gross proceeds of $235 million from a private placement and $44.2 million from its ATM Agreement.
Cash Position
As of September 30, 2024, Summit Therapeutics had cash and cash equivalents of $93.8 million and short-term investments in U.S. treasury securities amounting to $393.1 million. The company expects these resources will cover its operating cash needs for at least the next 12 months.
| Cash Position (in millions) | Amount |
|---|---|
| Cash and Cash Equivalents | $93.8 |
| Short-term Investments | $393.1 |
Future Prospects
Summit Therapeutics continues to pursue collaborations and licensing agreements to generate future revenue streams. The company has received funding from organizations like BARDA and CARB-X, which supports its ongoing R&D efforts and potential commercialization of product candidates once they receive regulatory approval.
Summit Therapeutics Inc. (SMMT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Summit Therapeutics Inc. (SMMT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Summit Therapeutics Inc. (SMMT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Summit Therapeutics Inc. (SMMT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.